Jobs
-
Senzer has announced that its breath-activated Systemic inhaled Delivery Device (SiDD) inhaler has won a 2018 Good Design award in the medical category. The Good Design Awards are presented by The Chicago Athenaeum: Museum of… Read more . . .
-
Biotech company Stem Cell Medicine (SCM) has announced that it licensed intranasal MSC-exo technology for the treatment of autism spectrum disorder (ASD) from Ramot, the Tel Aviv University Business Engagement Center. Preclinical studies have shown… Read more . . .
-
According to a report in Israeli financial newspaper Globes, Tel Aviv-based Syqe Medical has raised $50 million in a financing round led by Shavit Capital for continued development of its medicinal plants inhaler. Shavit Capital… Read more . . .
-
The FDA has approved Acorda’s Inbrija levodopa DPI for the treatment of OFF episodes in Parkinson’s disease patients taking carbidopa/levodopa, the company said. Inbrija is expected to be available to patients in the US in… Read more . . .
-
According to Teva, the FDA has approved the company’s sNDA for ProAir Digihaler dry powder albuterol smart inhaler for the treatment or prevention of bronchospasm in patients aged 4 and over. The FDA initially approved… Read more . . .
-
NPXe has announced the enrollment of the first patient in a Phase 3 study of Xenex inhaled xenon gas for the treatment of post cardiac arrest syndrome (PCAS). The FDA granted Fast Track designation to… Read more . . .
-
The annual Drug Delivery to the Lungs meeting once again experienced significant growth in attendance and sponsorship, as DDL 2018 drew more than 850 attendees and 110 exhibitors to the Edinburg International Conference Centre. Many… Read more . . .
-
The European Commission has approved AstraZeneca’s Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of COPD, the company has announced. The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion regarding… Read more . . .
-
Aradigm Corporation says that it has scheduled a meeting with the FDA to discuss results from the Phase 3 ORBIT-3 and ORBIT-4 trials of Apulmiq (formerly Linhaliq) dual release inhaled ciprofloxacin for the treatment of… Read more . . .
-
According to US-based ARS Pharmaceuticals, the company has raised $20 million in Series C financing for clinical development of its ARS-1 epinephrine nasal spray for the treatment of anaphylaxis. The financing round was led by… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland